Citations

Clear

12 citation(s) found for "Smith, Nathan".

Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs
Elliott, A. Bowes, Juresic, Sanny , Siegel, Leslie R. , Smith, Nathan T. , Siegel, Leslie, Elliott, Abigail

Mayo Clinic

The Clinical Journal of Pain | November 13, 2025 | Volume: 42 | Issue: 2 | Pages: No page available

10.1097/ajp.0000000000001341 | PMID 41230625 Get It

Objectives: The primary objective of this article was to examine literature from the last 10 years surrounding cardiovascular risks associated with NSAID use. Methods: A systematic search was developed to include randomized control trials and systematic review meta-analyses that focused on the cardiovascular effects associated with NSAID use. Results: The search and screen identified 10 articles published in the last 10 years to be included in the review. Discussion: The most common cardiovascular risks studied in the included literature were hemodynamic effects and myocardial infarction. The evidence in the included studies suggests that concerns of adverse hemodynamic effects may be overstated with short-term NSAID use. Myocardial infarction was shown to be a very serious, but rare, side effect associated with NSAID use. Practitioners should weigh this risk when using NSAIDs in patients with an increased risk of MI at baseline. Other included studies described risks of Kounis syndrome, QTc prolongation, and potential reversal of right ventricular dysfunction in patients using NSAIDs.
Improving Skeletal Muscle Relaxant Stewardship
Smith, Nathan T. , Bye, Kyo , Pitterle, Alyssa, Siegel, Leslie R. , Ming, Emily, Lewis, Ryan, Cunningham, Julie L. , Bye, Katelyn, Lewis, Ryan

Mayo Clinic

Journal of Pain & Palliative Care Pharmacotherapy | September 8, 2025 | Volume: 39 | Issue: 3 | Pages: 445-445

10.1080/15360288.2025.2533676 Get It

Post-Operative Bleed Risks Associated with Perioperative Nonsteroidal Anti-Inflammatory Drugs: A Narrative Review
Seitz, Laura Louise , Juresic, Sanny , Siegel, Leslie R. , Smith, Nathan T. , Seitz, Laura L , Siegel, Leslie

Mayo Clinic

Journal of Pain & Palliative Care Pharmacotherapy | August 19, 2025 | Volume: 39 | Issue: 4 | Pages: 518-524

10.1080/15360288.2025.2547839 | PMID 40828145 Get It

Breaking barriers: A journey towards comprehensive care and understanding for patients with sickle cell disease
Bye, Kyo , Juresic, Sanny , Rouse, Rachelle, Smith, N., Bye, Katelyn N , Smith, Nathan T. , Bye, Katelyn N

Mayo Clinic

American Journal of Health-System Pharmacy | June 27, 2025 | Volume: 82 | Issue: 17 | Pages: e778-e781

10.1093/ajhp/zxaf167 | PMID 40576453 Get It

A pilot single-arm, pragmatic trial in progress of in-home versus in-clinic subcutaneous nivolumab administration through Cancer Care (connected access and remote expertise) Beyond Walls (CCBW) program.
Lou, Yanyan , Mazza, Gina L. , Howard, Chanice, Confiado, Sunnie, Baskin, Amber, Jackson, Alexis, Fritsche, Angela Hazel, Lopez, Kai Castrezana , Brown, Jade, Nolan, Luci, Chapin, Dustin, Beliles, Gregory, Tan, Winston, Kharfan‐Dabaja, Mohamed A. , Nowakowski, Grzegorz S. , Dronca, Roxana , Mazza, Gina L , Elantably, Dina , Jones, Jeremy C , Jackson, Alexis, Lopez, Kaila, Nolan, Luci, Smith, Nathan , Willman, Cheryl L.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps1657 Get It

TPS1657 Background: Cancer treatments are traditionally administered in clinical settings, which can isolate patients from their familiar environments and exacerbate physical, psychosocial, and financial burdens. Travel requirements further amplify these challenges, particularly for underserved populations. Studies indicate that patients prefer receiving care at home, and international models have demonstrated the safety of home-delivered chemotherapy since the 1990s; however, no U.S. clinical trial data exists. In response, Mayo Clinic has developed the Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) program, a distributed cancer care delivery model that expands access to quality cancer care by bringing it to the home environment, providing in-home cancer treatment, lab testing, telemedicine, and community paramedic support. This trial evaluates the safety, acceptability, and impact of home-based subcutaneous (SC) nivolumab (Nivo) administration compared to in-clinic treatment within the CCBW initiative. Methods: This open-label, single-arm trial evaluates the impact of SC Nivo administration location—home versus infusion center—on patient reported cancer care experience, patient-preferred treatment location, acceptability, safety, and patient-reported outcomes. Eligible adult patients (ECOG 0-1) receiving IV Nivo for an FDA-approved indication and residing within 75 miles of Mayo Clinic Florida will transition to SC Nivo, receiving two initial in-clinic cycles. If tolerated without injection reactions, four cycles will be administered at home before resuming in-clinic treatment. Exclusion criteria include concurrent investigational/standard treatments or contraindications to immunotherapy. Fifty patients will be enrolled, with an estimated 75% (n=38) providing cancer care ratings after 8 weeks in-clinic and 8 weeks at-home, offering 85% power to detect a mean difference in ratings of 0.50 standard deviations. The primary endpoint is within-patient change in cancer care rating (0–10 scale, CAHPS Cancer Care Survey) comparing 8 weeks of in-clinic vs. at-home care. Secondary endpoints include patient-preferred treatment location, comfort with home injections, safety (grade 3+ adverse events), function (EORTC QLQ-F17), symptoms (PRO-CTCAE), side effect impact (GP5), and healthcare utilization (ER visits, hospitalizations). Cost will be assessed as a tertiary endpoint. The trial has FDA approval (IND #170079), Mayo Clinic IRB approval (#23009663), and ClinicalTrials.gov registration (NCT06265285). Enrollment began in April 2024, with an expected accrual period of 24 months. To date, 10 patients have been enrolled, and final analysis is expected 2.5 years after trial activation. Clinical trial information: NCT06265285 .
Identification of education gaps for pharmacists treating transgender and gender‐diverse patients: A quality initiative at a single academic health system
Engstrom, Kellyn , Brown, Caitlin S. , Lemke, Adley , Davis, K.A. , Moore, Elise , Davidge‐Pitts, Caroline , Mattson, Alicia E , Wright, Jessica , Smith, Nathan T. , Manuel, Francis C. , Wright, Jessica A , Lemke, Adley I , Davis, Katherine

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 11, 2025 | Volume: 8 | Issue: 4 | Pages: 264-270

10.1002/jac5.70016 Get It

AbstractBackgroundTransgender and gender‐diverse (TGD) patients experience challenges and disparities when seeking health care across a multitude of settings. Studies have demonstrated that TGD individuals experience bias when interacting with health care providers, including pharmacists in the community and hospital settings. Without proper training, pharmacists are less likely to be prepared to provide equitable and optimal patient care to TGD patients. This quality improvement initiative aimed to identify gaps in pharmacist knowledge and comfort with regard to TGD health care.MethodsA 29‐item reflective questionnaire was designed to collect information on pharmacist training and experiences in caring for TGD patients. The survey was distributed via email to all 490 pharmacists within a single health system and responses were collected from October 23, 2023 to November 3, 2023.ResultsA total of 116 pharmacists completed the survey, for a response rate of 24%. Although 77% of respondents reported caring for a TGD patient, only 21% reported receiving any formal education or training on TGD health care. While 83% of respondents agreed that formal education on TGD health care is important, and 90% indicated that education on gender‐affirming therapy is important, a majority of pharmacists disagreed that they were comfortable with making recommendations and providing counseling on gender‐affirming therapy. A majority of pharmacists were interested in formal education and engaging in departmental initiatives to improve TGD care.ConclusionsThere was a gap in confidence and education in caring for TGD patients among pharmacists practicing in a single academic institution. Pharmacists reported that more education is warranted to bridge current gaps in pharmacist comfort and TGD health care.
Intravenous Magnesium Sulfate as an Adjunct to Intravenous Ketamine for Acute Pain: A Case Series
Smith, Nathan A. , Juresic, Sanny , Lor, Kia, Schmidt, Carrie, Howrigon, Annie Bell, Olatoye, Oludare, Smith, Nathan, Bell Howrigon, Annie, Schmidt, Carrie

Mayo Clinic

Journal of Pain & Palliative Care Pharmacotherapy | December 13, 2024 | Volume: 39 | Issue: 2 | Pages: 229-236

10.1080/15360288.2024.2441794 | PMID 39671296 Get It

Navigating the Postoperative Management of Remifentanil-Induced Hyperalgesia: A Case Report
Smith, Nathan T. , Fernholz, Ryan, Juresic, Sanny

Mayo Clinic

Journal of Pain & Palliative Care Pharmacotherapy | September 9, 2024 | Volume: 38 | Issue: 4 | Pages: 373-378

10.1080/15360288.2024.2400901 | PMID 39250604 Get It

Time to unlock pain relief? A critical review of the patient-controlled analgesia 4-hour lockout parameter
Kiel, Alexander , Warner, Nafisseh S. , Smith, N., Kiel, Alexander M , Smith, Nathan T. , Warner, Nafisseh

Mayo Clinic

Pain Medicine | August 21, 2024 | Volume: 26 | Issue: 1 | Pages: 1-2

10.1093/pm/pnae087 | PMID 39167117 Get It